Clinically, serum IL-6 concentrations were significantly higher in patients with breast cancer compared with healthy controls, and IL-6 serum levels were significantly higher in patients with metastatic breast cancer than patients without metastasis [55]. This evidence concerns the gene IL6 and breast carcinoma.